secwatch.observer — SEC 8-K summary
======================================

Issuer:     PTC THERAPEUTICS, INC. (PTCT)
CIK:        0001070081
Form:       8-K
Filed at:   2025-12-29T23:59:59+00:00
Accession:  0001104659-25-124837
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

PTC Therapeutics sells remaining Evrysdi royalty stake to Royalty Pharma for $240M upfront
--------------------------------------------------------------------------------

- Sold remaining 9.5111%/16.6666% royalty interest in Evrysdi worldwide net sales for $240M upfront cash.
- Up to three additional $20M payments contingent on Royalty Pharma receiving >$347M (2027), $363M (2028), $379M (2029) in royalty payments.
- After closing, Royalty Pharma owns 100% of the Evrysdi royalty; PTC retains no interest.
- Transaction effective December 29, 2025, under Amendment No. 2 to existing royalty purchase agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070081/000110465925124837/0001104659-25-124837-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070081/000110465925124837/tmb-20251229x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-124837

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer